source
- Neurocrine’s rare-disease drug approved but later linked to deaths and serious side effectsNeurocrine Biosciences received regulatory approval for a rare‑disease therapy after a small clinical trial showed modest efficacy and side effects that were considered manageable. The decision was…
- July biopharma layoffs down 94% YoY, 466 jobs cut across six companiesJuly saw a sharp decline in biopharma workforce reductions, with only 466 employees affected, a 94% drop compared with the same month last year. BioSpace data shows six companies announced or proj…